CHICAGO (MedPage Today) -- A therapy aimed at reviving the immune response to advanced melanoma generated durable responses in long-term follow-up of an early clinical trial, a researcher said here. via MedPageToday.com - medical news plus CME for physicians Read More Here..
No comments:
Post a Comment